Comments on: Dendreon Immune-Booster for Prostate Cancer Extends Survival 4.1 Months

By: Michael Milken, 60,000 Deaths, and the Story of Dendreon | Deep Capture: exposing the crime of naked short selling

Tue, 15 Sep 2009 17:10:24 +0000

[...] it indeed it was. The data presented that day showed that Provenge lowers the risk of prostate cancer death by 22.5 percent, with little or no [...]

By: Michael Milken, 60,000 Deaths, and the Story of Dendreon (Chapter 1 of 15) | Deep Capture: exposing the crime of naked short selling

Fri, 19 Jun 2009 02:33:39 +0000

[...] it indeed it was. The data presented that day showed that Provenge lowers the risk of prostate cancer death by 22.5 percent, with little or no [...]

By: Dendreon Update: Stock Back Up After-Hours, More Fortunes Made/Lost! | IguanaBio - A Daily Biotech and Pharma Tabloid - Gossip, News, Research, Humor and Updates on the Latest Events in Biotech and Pharma - Unique, Insightful, Truthful, Sometimes Sneaky

Tue, 28 Apr 2009 23:49:21 +0000

[...] Data released showing an extended median survival of 4.1 months and increased 3-year survival by 38% compared to placebo. Study shows a reduction of death by 22.5% vs placebo with a p-value of 0.032. [Xconomy] [...]

By: PROSTATE DRUG: Provenge lowers risk of death 22.5%, say much-awaited study data « Prosta-blog

Tue, 28 Apr 2009 22:51:04 +0000

[...] April 29, 2009 by Jim Tucker XCONOMY SEATTLE: Dendreon’s immune-stimulating therapy for prostate cancer, called Provenge, was able to improve median survival time by 4.1 months, and lowered the risk of death by 22.5 percent, according to long-awaited clinical trial results presented at the American Urological Association annual meeting today. READ MORE> [...]

By: Bob

Bob — Tue, 28 Apr 2009 20:15:06 +0000

“median survival time of more than 4 months will be considered a “home run”… sounds like your garden-variety stock analyst. Xconomy did not include any caveat whether Mr. Miller owns Dendreon stock…

We need better outcomes measures and metrics. 4.1 survival increase months over a 5 or 10 year disease? and at what cost?

p-values of 0.05 and below are better… 0.032 is still in the gray-zone of statistical significance that placebo is sufficiently different from Provenge.

The 0.032 value with a *lower* survival rate increase than the previous study (median 4.1 months to 4.5 months) makes this result-set stay on the fence.

By: Dendreon Reveals Data, NASDAQ Investigation Timeline, Fortunes | IguanaBio - A Daily Biotech and Pharma Tabloid - Gossip, News, Research, Humor and Updates on the Latest Events in Biotech and Pharma - Unique, Insightful, Truthful, Sometimes Sneaky

Tue, 28 Apr 2009 20:08:46 +0000